Treatment for recurrent hairy cell leukemia.

Cite item

Full Text


Aim. To give data on the frequency of recurrent hairy cell leukemia (HCL) and to characterize the immediate and late results of its treatment in this group of patients. Materials and methods. The data on the frequency of recurrences were analyzed in 165 patients with HCL after remission achieved by the purine analogue cladribin in the period 1995 to 2011. The treatment of recurrent HCL included splenectomy, interferon-α, cladribin, and rituximab. Results. After a course of cladribin therapy, the total frequency of recurrent HCL was 22%. The high (47%) frequency of recurrences was found in young patients (less than 45 years) as compared to that (9%) in older patients. A combination of cladribin and rituximab showed a high efficacy in treating the early recurrence of HCL. Conclusion. The differences found in the frequency of recurrences give grounds to incorporate rituximab into the standard therapy regimen for HCL in young patients and in patients with early disease recurrence.

Full Text

Лечение рецидивов волосатоклеточного лейкоза. - Резюме. Цель исследования. Представить данные о частоте рецидивов волосатоклеточного лейкоза (ВКЛ), охарактеризовать непосредственные и отдаленные результаты лечения этой группы больных. Материалы и методы. Проанализированы данные о частоте рецидивов у 165 больных ВКЛ после ремиссии, достигнутой c помощью аналога пурина - кладрибина - в период с 1995 по 2011 г. Лечение в рецидиве включало спленэктомию, a-интерферон, кладрибин, ритуксимаб. Результаты. Общая частота рецидивов ВКЛ после курса терапии кладрибином составила 22%. Выявлена высокая частота рецидивов (47%) у пациентов молодого возраста (моложе 45 лет) по сравнению с 9% рецидивов у пациентов старшей возрастной группы. Показана большая эффективность сочетания кладрибина и ритуксимаба при раннем рецидиве ВКЛ. Заключение. Выявленные различия по частоте рецидивов дают основания для включения ритуксимаба в стандартную схему терапии ВКЛ у пациентов молодого возраста и у больных с ранним рецидивом заболевания.


  1. Bouroncle B., Wiseman B., Doan C. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.
  2. Catovsky D., Pettit J., Galton D. et al. Leukaemic reticuloendotheliosis ("hairy" cell leukaemia): A distinct clinico-pathological entity. Br J Haematol 1974; 26: 9-27.
  3. Fu S., Winchester R., Rai K., Kunkel H. Hairy cell leukemia: Proliferation of a cell with phagocytic and B-lymphocyte properties. Scand J Immunol 1974; 3: 847-851.
  4. Haak H., de Man J.C.H., Hijmans W. et al. Further evidence for the lymphocytic nature of leukaemic reticuloendotheliosis (hairy cell leukaemia). Br J Haematol 1974; 27: 31-38.
  5. Seshadri R., Brown E., Zipursky A. Leukemic reticuloendotheliosis. A failure of monocyte production. New Engl J Med 1976; 295: 181-184.
  6. Quesada J., Reuben J., Manning J. et al. Alpha interferon for the induction of remission in hairy cell leukemia. New Engl J Med 1984; 310: 15-18.
  7. Glaspy J.A., Souza L., Scates S. et al. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon alpha 2b. J Immunother 1992; 11: 198-208.
  8. Tiacci Е., Trifonov V., Schiavoni G. et al. BRAF Mutations in Hairy-Cell Leukemia N Engl J Med 2011; 364: 2305-2315.
  9. Luke J.J., Hodi F.S. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clin Cancer Res 2012; 18 (1): 9-14.
  10. Else M., Ruchlemer R., Osuji N. et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12,5 years. Cancer 2005; 104: 2442-2448.
  11. ChadhaP., Rademaker A.W., Mendiratta P. et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 1: 241-246.
  12. Konwalinka G., Schirmer M., Hilbe W. et al. Minimal residual in hairy cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood cells, Mol, Dis 1995; 21: 142-151.
  13. Tallman M., Hakimian D., Kopecky K. et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665-1670.
  14. Tallman M., Hakimian D., Rademaker A. et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954-1959.
  15. Else M., Dearden C.E., Matutes E. et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 6: 733-740.
  16. Jones G., Parry-Jones N., Wilkins B. et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 2012; 156: 2: 186-195.
  17. Zinzani P.L., Pellegrini C., Stefoni V. et al. Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer 2010; 116: 4788-4792.
  18. Thomas D., O'Brien S., Bueso-Ramos C. et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906-3911.
  19. Kreitman R.J. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 1: 117-133.
  20. Cervetti G., Galimberti S., Andreazzoli F. et al. Rituximab as treatment for minimal residual disease in hairy cell leukemia: extended follow up. Br J Haematol 2008; 143: 296-298.
  21. Else M., Dearden C.E., Matutes E. et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011; 52: Suppl 2: 75-78.
  22. Kreitman R., Stetler-Stevenson M., Wilson W. et al. Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia. Blood 2011; 118: Abstract 3909.
  23. Ахмедов А.Г. Клинические особенности, кроветворение и иммунитет при волосатоклеточном лейкозе: Дис. …канд. мед. Наук. М 1985.
  24. Аль-Ради Л.С. Волосатоклеточный лейкоз: особенности течения, современная тактика терапии: Дис. ... канд. мед. наук. М 2008.
  25. Cheson B., Sorensen J., Vena D. et al. Treatment of hairy cell leukemia with 2-chloro-deoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-3015.
  26. Laura F., Lenoci M., Annino L. et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046-1050.
  27. Ravandi F., O'Brien S., Jorgensen J. et al. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118 (14): 3818-3823.
  28. Saven A., Cheung W., Smith I. et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978-983.
  29. Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клин онкогематол 2009; 2: 111-120.

Copyright (c) 2012 Al'-Radi L.S., Pivnik A.V., Zingerman B.V., Kravchenko S.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies